PEHA Stock Overview
Operates in the pharmaceutical industry in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
PT Phapros Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp296.00 |
| 52 Week High | Rp1,000.00 |
| 52 Week Low | Rp280.00 |
| Beta | 0.29 |
| 11 Month Change | -22.92% |
| 3 Month Change | -18.23% |
| 1 Year Change | -46.67% |
| 33 Year Change | -74.26% |
| 5 Year Change | -69.48% |
| Change since IPO | -83.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| PEHA | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | 1.4% | -2.4% | -2.2% |
| 1Y | -46.7% | -9.4% | 9.3% |
Return vs Industry: PEHA underperformed the ID Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: PEHA underperformed the ID Market which returned 9.3% over the past year.
Price Volatility
| PEHA volatility | |
|---|---|
| PEHA Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.6% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: PEHA has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: PEHA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 1,384 | Ida Kurniasih | www.phapros.co.id |
PT Phapros Tbk, together with its subsidiaries, operates in the pharmaceutical industry in Indonesia. The company operates through Ethical; Over the Counter (OTC) Drugs; Ethical; Generic Drugs Bearing; and Toll-in Manufacturing segments. It offers OTC drugs, including Antimo Anak, Livron B Plek, Noza, Hemorogard, Bioron, and others through pharmacies, retail, and drug stores.
PT Phapros Tbk Fundamentals Summary
| PEHA fundamental statistics | |
|---|---|
| Market cap | Rp248.64b |
| Earnings (TTM) | -Rp46.65b |
| Revenue (TTM) | Rp806.40b |
0.3x
P/S Ratio-5.3x
P/E RatioIs PEHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEHA income statement (TTM) | |
|---|---|
| Revenue | Rp806.40b |
| Cost of Revenue | Rp431.91b |
| Gross Profit | Rp374.49b |
| Other Expenses | Rp421.15b |
| Earnings | -Rp46.65b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.54 |
| Gross Margin | 46.44% |
| Net Profit Margin | -5.79% |
| Debt/Equity Ratio | 106.2% |
How did PEHA perform over the long term?
See historical performance and comparison